The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival

References

• Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399–408.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008;26:4497–4503.
   PubMed Web of Science ®Google Scholar
• Gottardi D, Alfarano A, DeLeo AM, et al. In leukaemic CD5(+) B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996;94:612–618.
   PubMed Web of Science ®Google Scholar
• Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379–3389.
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003;21:841–894.
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004;103:4389–4395.
   PubMed Web of Science ®Google Scholar
• Kipps TJ. The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:415–424.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Chiorazzi N. Where is the biology of CLL leading us? Semin Cancer Biol 2010;20:361–362.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012–1020.
   PubMed Web of Science ®Google Scholar
• Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703–710.
   PubMed Web of Science ®Google Scholar
• George M, Vaughn JH. In vitro cell migration as a model for delayed hypersensitivity. Proc Soc Exp Biol Med 1962;111:514–521.
   PubMed Web of Science ®Google Scholar
• Bloom BR, Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966;153:80–82.
   PubMed Web of Science ®Google Scholar
• Sun HW, Bernhagen J, Bucala R, Lolis E. Crystal structure at 2.6-angstrom resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 1996;93:5191–5196.
   PubMed Web of Science ®Google Scholar
• Sun H, Bernhagen J, Bucala R, Lolis E. Crystal structure of MIF reveals a novel architecture and solvent accessible channel. J Investig Med 1996;44:A199.
   Web of Science ®Google Scholar
• Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF)-the potential missing link. QJM 2010;103:831–836.
   PubMed Web of Science ®Google Scholar
• Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895–1902.
   PubMed Web of Science ®Google Scholar
• Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999;189:341–346.
   PubMed Web of Science ®Google Scholar
• Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002;99:345–350.
   PubMed Web of Science ®Google Scholar
• Bernhagen J, Bacher M, Calandra T, et al. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J Exp Med 1996;183:277–282.
   PubMed Web of Science ®Google Scholar
• Bacher M, Metz CN, Calandra T, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996;93:7849–7854.
   PubMed Web of Science ®Google Scholar
• Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467–1476.
   PubMed Web of Science ®Google Scholar
• Meyer-Siegler K, Hudson PB. Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. Urology 1996;48:448–452.
   PubMed Web of Science ®Google Scholar
• Bando H, Matsumoto G, Bando M, et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002;93:389–396.
   PubMedGoogle Scholar
• Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S. Macrophage migration inhibitory factor (MIF): its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 2003;995:171–182.
   PubMed Web of Science ®Google Scholar
• Chesney J, Metz C, Bacher M, Peng T, Meinhardt A, Bucala R. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med 1999;5:181–191.
   PubMed Web of Science ®Google Scholar
• Stumptner-Cuvelette P, Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim Biophys Acta 2002;1542:1–13.
   PubMed Web of Science ®Google Scholar
• Unanue ER. Antigen-presenting function of the macrophage. Annu Rev Immunol 1984;2:395–428.
   PubMed Web of Science ®Google Scholar
• Long EO. Intracellular traffic and antigen processing. Immunol Today 1989;10:232–234.
   PubMedGoogle Scholar
• Harding CV, Unanue ER. Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules. Cell Regul 1990;1:499–509.
   PubMedGoogle Scholar
• Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259–293.
   PubMed Web of Science ®Google Scholar
• Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 1991;88:3150–3154.
   PubMed Web of Science ®Google Scholar
• Neefjes JJ, Stollorz V, Peters PJ, Geuze HJ, Ploegh HL. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 1990;61:171–183.
   PubMed Web of Science ®Google Scholar
• Beswick EJ, Bland DA, Suarez G, Barrera CA, Fan X, Reyes VE. Helicobacter pylori binds to CD74 on gastric epithelial cells and stimulates interleukin-8 production. Infect Immun 2005;73:2736–2743.
   PubMed Web of Science ®Google Scholar
• Shachar I, Flavell RA. Requirement for invariant chain in B cell maturation and function. Science 1996;274:106–108.
   PubMed Web of Science ®Google Scholar
• Kenty G, Martin WD, Van Kaer L, Bikoff EK. MHC class II expression in double mutant mice lacking invariant chain and DM functions. J Immunol 1998;160:606–614.
   PubMed Web of Science ®Google Scholar
• Kenty G, Bikoff EK. BALB/C invariant chain mutant mice display relatively efficient maturation of CD4+ T cell in the periphery and secondary proliferative responses elicited upon peptide challenge. J Immunol 1999;163:232–242.
   PubMed Web of Science ®Google Scholar
• Rajagopalan G, Smart MK, Krco CJ, David CS. Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain. J Immunol 2002;169:1774–1783.
   PubMed Web of Science ®Google Scholar
• Matza D, Lantner D, Bogoch Y, Flaishon L, Hershkoviz R, Shachar I. Invariant chain induces B cell maturation in a process which is independent of its chaperonic activity. Proc Natl Acad Sci USA 2002;99:3018–3023.
   PubMed Web of Science ®Google Scholar
• Meyer-Siegler KL, Leifheit EC, Vera PL. Inhibition of macrophage migration inhibitory factor decreases proliferation and cytokine expression in bladder cancer cells. BMC Cancer 2004;4:34–45.
   PubMed Web of Science ®Google Scholar
• Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595–606.
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, et al. Invariant chain expression in gastric cancer. Cancer Lett 2001;168:87–91.
   PubMed Web of Science ®Google Scholar
• Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639–1651.
   PubMed Web of Science ®Google Scholar
• Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996;20:64–71.
   PubMed Web of Science ®Google Scholar
• Datta MW, Shahsafaei A, Nadler LM, Freeman GJ, Dorfman DM. Expression of MHC class II-associated invariant chain (Ii;CD74) in thymic epithelial neoplasms. Appl Immunohistochem Mol Morphol 2000;8:210–215.
   PubMedGoogle Scholar
• Lazova R, Moynes R, May D, Scott G. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma. Cancer 1997;79:2115–2124.
   Google Scholar
• Narni F, Kudo J, Mars W, et al. HLA-DR-associated invariant chain is highly expressed in chronic lymphocytic leukemia. Blood 1986;68:372–377.
   PubMed Web of Science ®Google Scholar
• Veenstra H, Jacobs P, Dowdle EB. Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Cell Immunol 1996;171:68–73.
   PubMed Web of Science ®Google Scholar
• Mizue Y, Nishihira J, Miyazaki T, et al. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med 2000;5:397–403.
   PubMed Web of Science ®Google Scholar
• Leth-Larsen R, Lund R, Hansen HV, et al. Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Mol Cell Proteom 2009;8:1436–1449.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705–3711.
   PubMed Web of Science ®Google Scholar
• Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991;173:1213–1225.
   PubMed Web of Science ®Google Scholar
• Cariappa A, Mazo IB, Chase C, et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. Immunity 2005;23:397–407.
   PubMed Web of Science ®Google Scholar
• Matza D, Kerem A, Shachar I. Invariant chain, a chain of command. Trends Immunol 2003;24:246–248.
   Web of Science ®Google Scholar
• Matza D, Wolstein O, Dikstein R, Shachar I. Invariant chain induces B cell maturation by activating TAFII105-NF-kB dependent transcription program. J Biol Chem 2001;276:27203–27206.
   PubMed Web of Science ®Google Scholar
• Matza D, Kerem A, Lantner F, Shachar I. Invariant chain induced B cell differentiation requires intramembrane - proteolytic release of the cytosolic domain. Immunity 2002;17:549–560.
   PubMed Web of Science ®Google Scholar
• Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis (RIP) processed protein family. Mol Biol Cell 2005;16:5061–5069.
   PubMed Web of Science ®Google Scholar
• Starlets D, Gore Y, Binsky I, et al. Cell surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107:4807–4816.
   PubMed Web of Science ®Google Scholar
• Gore Y, Starlets D, Maharshak N, et al. Macrophage migration inhibitory factor (MIF) induces B cell survival by activation of a CD74/CD44 receptor complex. J Biol Chem 2008;283:2784–2792.
   PubMed Web of Science ®Google Scholar
• Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836–841.
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841–846.
   PubMed Web of Science ®Google Scholar
• Tokoyoda K, Egawa T, Sugiyama T, Choi B, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004;20:707–718.
   PubMed Web of Science ®Google Scholar
• Sapoznikov A, Pewzner-Jung Y, Kalchenko V, Krauthgamer R, Shachar I, Jung S. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol 2008;9:388–395.
   PubMed Web of Science ®Google Scholar
• Maharshak N, Cohen S, Lantner F, et al. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol 2010;16:3258–3266.
   PubMed Web of Science ®Google Scholar
• van der Voort R, Taher TE, Wielenga VJ, et al. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 1999;274:6499–6506.
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074–3086.
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V, Morrison H, Matzke A, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007;18:76–83.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915–925.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Comoglio PM. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci 2003;28:527–533.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408–417.
   PubMed Web of Science ®Google Scholar
• Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284–292.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth-factor is essential for liver development. Nature 1995;373:699–702.
   PubMed Web of Science ®Google Scholar
• Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995;373:702–705.
   PubMed Web of Science ®Google Scholar
• Tulasne D, Foveau B. The shadow of death on the MET tyrosine kinase receptor. Cell Death Differ 2008;15:427–434.
   PubMed Web of Science ®Google Scholar
• Gordin M, Tesio M, Cohen S, et al. c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74. J Immunol 2010;185:2020–2031.
   PubMed Web of Science ®Google Scholar
• Lantner F, Starlets D, Gore Y, et al. CD74 induces TAp63 expression leading to B cell survival. Blood 2007;110:4303–4311.
   PubMed Web of Science ®Google Scholar
• Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305–316.
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714–718.
   PubMed Web of Science ®Google Scholar
• Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708–713.
   PubMed Web of Science ®Google Scholar
• Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev 2009;8:244–249.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Mechanisms of disease: systemic lupus erythematosus. N Engl J Med 2008;358:929–939.
   PubMed Web of Science ®Google Scholar
• Lapter S, Ben-David H, Sharabi A, et al. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide. Immunology 2011;132:87–95.
   PubMed Web of Science ®Google Scholar
• Leng L, Chen L, Fan J, et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J Immunol 2011;186:527–538.
   PubMed Web of Science ®Google Scholar
• Waisman A, Shoenfeld Y, Blank M, Ruiz PJ, Mozes E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus-erythematosus in mice is encoded by a V(H)4 gene segment. Int Immunol 1995;7:689–696.
   PubMed Web of Science ®Google Scholar
• Luger D, Dayan M, Zinger H, Liu JP, Mozes E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004;24:579–590.
   PubMed Web of Science ®Google Scholar
• Lapter S, Marom A, Meshorer A, et al. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis Rheum 2009;60:3744–3754.
   PubMed Web of Science ®Google Scholar
• Binsky I, Haran M, Starlets D, et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 2007;104:13408–13413.
   PubMed Web of Science ®Google Scholar
• Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994;56:559–564.
   PubMed Web of Science ®Google Scholar
• Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798–1801.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Zachariae CO, Norihisa Y, Ortaldo JR, Hishinuma A, Matsushima K. IL-8 gene expression and production in human peripheral blood lymphocyte subsets. J Immunol 1991;146:3815–3823.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neurooncology 2005;7:122–133.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Johnson MM, Do KA, et al. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 2003;120:452–456.
   PubMed Web of Science ®Google Scholar
• Binsky I, Lantner F, Grabovsky V, et al. TAp63 regulates VLA-4 expression and CLL cell migration to the BM in a CD74 dependent manner. J Immunol 2010;184:4761–4769.
   PubMed Web of Science ®Google Scholar
• Ghia P, Granziero L, Chilosi M, Caligaris-Cappio F. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002;12:149–155.
   PubMed Web of Science ®Google Scholar
• Chappell CP, Clark EA. Survival niches: B cells get MIFed as well as BAFFled by dendritic cells. Immunol Cell Biol 2008;86:487–488.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008;140:537–546.
   PubMed Web of Science ®Google Scholar
• Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008;111:865–873.
   PubMed Web of Science ®Google Scholar
• Rossi D, Zucchetto A, Rossi FM, et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008;93:1575–1579.
   PubMed Web of Science ®Google Scholar
• de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with alpha 4 beta 1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999;13:266–274.
   PubMed Web of Science ®Google Scholar
• de la Fuente MT, Casanova B, Moyano JV, et al. Engagement of alpha 4 beta 1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002;71:495–502.
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clini Cancer Res 2007;13:5556S–5563S.
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. J Clin Oncol 2009;27(15 Suppl.): Abstract 8593.
   Web of Science ®Google Scholar
• Hertlein E, Triantafillou G, Sass EJ, et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 2010;116:2554–2558.
   PubMed Web of Science ®Google Scholar